Please try another search
Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.
Name | Age | Since | Title |
---|---|---|---|
Michael C. Pearce | 59 | 2013 | Independent Director |
Steven D. Scheiwe | 60 | 2013 | Director |
Jonathan M. Couchman | 51 | 2013 | Chairman, CEO, President, CFO & Principal Accounting Officer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review